blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4262798

EP4262798 - TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  22.09.2023
Database last updated on 14.06.2024
FormerThe international publication has been made
Status updated on  25.06.2022
Formerunknown
Status updated on  19.01.2022
Most recent event   Tooltip23.02.2024Change: Validation statespublished on 27.03.2024  [2024/13]
Applicant(s)For all designated states
Bial-Portela & CA, S.A.
À Avenida da Siderurgia Nacional
4745-457 S. Mamede do Coronado / PT
[2023/43]
Inventor(s)01 / SOARES DA SILVA, Patrício Manuel Vieira Araújo
4745-457 S. Mamede de Coronado / PT
02 / DA COSTA DE PINHO ROCHA, José Francisco
4745-457 S. Mamede de Coronado / PT
 [2023/43]
Representative(s)Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
[2023/43]
Application number, filing date21840202.217.12.2021
[2023/43]
WO2021PT50044
Priority number, dateGB2020001995417.12.2020         Original published format: GB 202019954
GB2021000613329.04.2021         Original published format: GB 202106133
GB2021000982607.07.2021         Original published format: GB 202109826
[2023/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022131944
Date:23.06.2022
Language:EN
[2022/25]
Type: A1 Application with search report 
No.:EP4262798
Date:25.10.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 23.06.2022 takes the place of the publication of the European patent application.
[2023/43]
Search report(s)International search report - published on:EP23.06.2022
ClassificationIPC:A61K31/4439, A61K31/165, A61K31/198, A61K45/06, A61P25/16
[2023/43]
CPC:
A61K31/4439 (EP,KR,US); A61K31/165 (EP); A61K31/198 (EP,US);
A61K45/06 (EP); A61P25/16 (EP,KR,US)
C-Set:
A61K31/165, A61K2300/00 (EP);
A61K31/198, A61K2300/00 (EP);
A61K31/4439, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/43]
Extension statesBA17.07.2023
ME17.07.2023
TitleGerman:BEHANDLUNGSSCHEMATA FÜR FRÜH IDIOPATHISCHE PARKINSON-KRANKHEIT[2023/43]
English:TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE[2023/43]
French:RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE[2023/43]
Entry into regional phase17.07.2023National basic fee paid 
17.07.2023Designation fee(s) paid 
17.07.2023Examination fee paid 
Examination procedure17.07.2023Amendment by applicant (claims and/or description)
17.07.2023Examination requested  [2023/43]
17.07.2023Date on which the examining division has become responsible
Fees paidRenewal fee
14.12.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[YD]  - BROOKS D J, "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY., GB, (20030801), vol. 74, no. 8, doi:10.1136/jnnp.74.8.1071, ISSN 0022-3050, pages 1071 - 1079, XP055900230 [YD] 1-44 * whole document, particularly abstract and introduction of p. 1071 *

DOI:   http://dx.doi.org/10.1136/jnnp.74.8.1071
 [YD]  - FERREIRA JOAQUIM J ET AL, "Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial", THE LANCET NEUROLOGY, ELSEVIER, AMSTERDAM, NL, (20151223), vol. 15, no. 2, doi:10.1016/S1474-4422(15)00336-1, ISSN 1474-4422, pages 154 - 165, XP029384199 [YD] 1-44 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1474-4422(15)00336-1
 [XP]  - NAKAMAGOE KIYOTAKA ET AL, "Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day", NEUROLOGICAL SCIENCES (TESTO STAMPATO), SPRINGER VERLAG, MILAN, IT, vol. 42, no. 11, doi:10.1007/S10072-021-05481-Y, ISSN 1590-1874, (20210804), pages 4813 - 4814, (20210804), XP037590756 [XP] 1-44 * the whole document *

DOI:   http://dx.doi.org/10.1007/s10072-021-05481-y
 [XP]  - FERREIRA JOAQUIM ET AL, "The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 429, doi:10.1016/J.JNS.2021.119422, ISSN 0022-510X, (20211001), (20211008), XP086818873 [XP] 1-44 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jns.2021.119422
 [AD]  - MARK STACY, "The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease", JOURNAL OF NEURAL TRANSMISSION, SPRINGER-VERLAG, VI, (20100620), vol. 117, no. 7, ISSN 1435-1463, pages 837 - 846, XP019853207 [AD] 1-44 * table 1 *
by applicantWO2009116882
 WO2010114404
 WO2010114405
 WO2013089573
 WO2016083875
    - FERREIRA J et al., Eur. J. Neurol., (20130000), vol. 20, pages 5 - 15
    - AQUINO CCFOX SH, Mov. Disord., (20150000), vol. 30, pages 80 - 89
    - CHAPUIS SOUCHCHANE LMETZ OGERBAUD LDURIF et al., Mov. Disord., (20050000), vol. 20, pages 224 - 30
    - POEWE W, Neurology, (20090000), vol. 72, pages 65 - 73
    - L. E. KISS et al., J. Med. Chem., (20100000), vol. 53, pages 3396 - 3411
    - FERREIRA et al., Lancet Neurol., (20160000), vol. 15, pages 154 - 65
    - LEES et al., JAMA Neurol., (20170000), vol. 74, pages 197 - 206
    - MIYASAKI JM et al., Neurology, (20020000), vol. 58, pages 11 - 17
    - FOX SH et al., Mov. Disord., (20110000), vol. 26, pages 2 - 41
    - OLANOW CW et al., Mov. Disord., (20040000), vol. 31, pages 1489 - 1496
    - RASCOL O et al., Mov. Disord., (20160000), vol. 31, pages 1489 - 1496
    - ANTONINI A et al., Lancet Neurol., (20090000), vol. 8, pages 929 - 937
    - STOCCHI F et al., Ann. Neurol., (20100000), vol. 68, pages 18 - 27
    - CARRARINI et al., Biomolecules, (20190000), vol. 9, page 388
    - BROOKS DJ, Neuropsychiatr. Dis. Treat., (20080000), vol. 4, no. 1, pages 39 - 47
    - FAHN S., Ann. Neurol., (20000000), vol. 47, pages S2 - S9
    - "UPDRS Program Members. Unified Parkinson's disease rating scale", FAHN SELTON RL, In Recent Developments in Parkinson's Disease, Macmillan Healthcare Information, (19870000), vol. 2, pages 293 - 304
    - STACY MHAUSER R., J. Neural. Transm., (20070000), vol. 114, pages 211 - 217
    - GOETZ C. et al., Mov. Disord., (20080000), vol. 23, pages 2129 - 70
    - HOEHN M.YAHR M., Neurology, (19670000), vol. 17, pages 427 - 42
    - CHAUDHURI K. et al., Mov. Disord., (20060000), vol. 21, pages 916 - 23
    - CHAUDHURI K. et al., Mov. Disord., (20070000), vol. 22, pages 1901 - 11
    - PETO V et al., Qual. Life Res., (19950000), vol. 4, pages 241 - 8
    - JENKINSON C et al., Age Ageing, (19970000), vol. 26, pages 353 - 7
    - STACY M. et al., Clin. Neuropharmacol., (20060000), vol. 29, pages 312 - 21
    - LEWITT PA, "Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics", Mov Disord, (20150000), vol. 30, no. 1, pages 64 - 72
    - OLANOW CW, "Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less", Mov Disord, (20190000), vol. 34, no. 6, pages 812 - 5
    - AQUINO CCFOX SH, "Clinical spectrum of levodopa-induced complications", Mov Disord., (20150000), vol. 30, no. 1, pages 80 - 9
    - CHAUDHURI KRJENNER PANTONINI A., "Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?", Mov Disord., (20190000), vol. 34, no. 6, pages 816 - 9
    - STACY M., "The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease", J Neural Transm., (20100000), vol. 117, no. 7, pages 837 - 46, XP019853207
    - BJORNESTAD AFORSAA EBPEDERSEN KFTYSNES OBLARSEN JPALVES G, "Risk and course of motor complications in a population-based incident Parkinson's disease cohort", Parkinsonism Relat Disord., (20160000), vol. 22, doi:10.1016/j.parkreldis.2015.11.007, pages 48 - 53, XP029362544

DOI:   http://dx.doi.org/10.1016/j.parkreldis.2015.11.007
    - SCOTT NWMACLEOD ADCOUNSELL CE, "Motor complications in an incident Parkinson's disease cohort", Eur J Neurol, (20160000), vol. 23, no. 2, pages 304 - 12
    - KIM H-JMASON SFOLTYNIE TWINDER-RHODES SBARKER RAWILLIAMS-GRAY CH, "Motor Complications in Parkinson's Disease: 13-Year Follow-up of the CamPaIGN Cohort.", Movement Disorders, (20200000), vol. 35, no. l, pages 185 - 90
    - LEWITT PACHAUDHURI KR, "Unmet needs in Parkinson disease: Motor and non-motor", Parkinsonism Relat Disord, (20200000), vol. 80, doi:10.1016/j.parkreldis.2020.09.024, pages S7 - S 12, XP086417948

DOI:   http://dx.doi.org/10.1016/j.parkreldis.2020.09.024
    - CHAPUIS SOUCHCHANE LMETZ OGERBAUD LDURIF F, "Impact of the motor complications of Parkinson's disease on the quality of life", Mov Disord, (20050000), vol. 20, no. 2, pages 224 - 30
    - HECHTNER MCVOGT TZOLLNER YSCHRODER SSAUER JBBINDER H et al., "Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries", Parkinsonism Relat Disord, (20140000), vol. 20, pages 969 - 74
    - WU JLIM E-CNADKARNI NVTAN E-KKUMAR PM, "The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore", Scientific Reports, (20190000), vol. 9, no. 1, page 9248
    - SOH S-EMORRIS MEMCGINLEY JL, "Determinants of health-related quality of life in Parkinson's disease: A systematic review", Parkinsonism & Related Disorders, (20110000), vol. 17, no. 1, pages 1 - 9, XP027590487
    - SCHRAG AQUINN N., "Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study", Brain, (20000000), vol. 123, pages 2297 - 305
    - FOUNDATION MJF, "Foundation MJF", Capturing and Elevating the Patient Voice, (20140000), URL: https://www.michaelifox.org/foundation/news-detail.php?captuling-and-elevating-the-patient-voice
    - PAHWA R, LYONS KE, "Levodopa-related wearing-off in Parkinson's disease:identification and management", Curr Med Res Opin, (20090000), vol. 25, no. 4, pages 841 - 9, XP009149221
    - HAUSER RAMCDERMOTT MPMESSING S, "Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease", Arch Neurol, (20060000), vol. 63, no. 12, pages 1756 - 60
    - OLANOW CWKIEBURTZ KRASCOL OPOEWE WSCHAPIRA AHEMRE M et al., "Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease", Mov Disord, (20130000), vol. 28, no. 8, pages 1064 - 71
    - KADASTIK-EERME LTABA NASSER TTABA P, "Factors associated with motor complications in Parkinson's disease", Brain and behavior, (20170000), vol. 7, no. 10, page e00837
    - STOCCHI F, "The levodopa wearing-off phenomenon in Parkinson's disease:pharmacokinetic considerations", Expert Opin Pharmacother, (20060000), vol. 7, no. 10, pages 1399 - 407
    - STOCCHI FJENNER POBESO JA, "When Do Levodopa Motor Fluctuations First Appear in Parkinson's Disease?", Eur Neurol, (20100000), vol. 63, no. 5, pages 257 - 66
    - OLANOW CWKIEBURTZ KODIN PESPAY AJSTANDAERT DGFERNANDEZ HH et al., "Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study", Lancet Neurol, (20140000), vol. 13, no. 2, doi:10.1016/S1474-4422(13)70293-X, pages 141 - 9, XP055416633

DOI:   http://dx.doi.org/10.1016/S1474-4422(13)70293-X
    - ANTONINI ASTOESSL AJKLEINMAN LSSKALICKY AMMARSHALL TSSAIL KR et al., "Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach", Curr Med Res Opin, (20180000), vol. 34, no. 12, pages 2063 - 73
    - SCHAPIRA AHBARONE PHAUSER RAMIZUNO YRASCOL OBUSSE M et al., "Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial", Neurology, (20110000), vol. 77, no. 8, pages 767 - 74
    - KATZENSCHLAGER RPOEWE WRASCOL OTRENKWALDER CDEUSCHL GCHAUDHURI KR et al., "Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial", Lancet Neurol, (20180000), vol. 17, no. 9, doi:10.1016/S1474-4422(18)30239-4, pages 749 - 59, XP085443992

DOI:   http://dx.doi.org/10.1016/S1474-4422(18)30239-4
    - LEWITT PALYONS KEPAHWA R, "Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study", Neurology, (20070000), vol. 68, no. 16, pages 1262 - 7
    - ANTONINI ATOLOSA EMIZUNO YYAMAMOTO MPOEWE WH, "A reassessment of risks and benefits of dopamine agonists in Parkinson's disease", Lancet Neurol, (20090000), vol. 8, no. 10, doi:10.1016/S1474-4422(09)70225-X, pages 929 - 37, XP026583639

DOI:   http://dx.doi.org/10.1016/S1474-4422(09)70225-X
    - ELMER LWJUNCOS JLSINGER CTRUONG DDCRISWELL SRPARASHOS S et al., "Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease", CNS Drugs., (20180000), vol. 32, no. 4, pages 387 - 98
    - FOX SH, KATZENSCHLAGER R, LIM SY, BARTON B, DE BIE RMA, SEPPI K, "International Parkinson and movement disorder society evidence-based medicine review:Update on treatments for the motor symptoms of Parkinson's disease", Mov Disord, (20180000), vol. 33, no. 8, pages 1248 - 66
    - KEATING GMLYSENG-WILLIAMSON KA, "Tolcapone: a review of its use in the management of Parkinson's disease", CNS Drugs, (20050000), vol. 19, no. 2, doi:10.2165/00023210-200519020-00006, pages 165 - 84, XP008047162

DOI:   http://dx.doi.org/10.2165/00023210-200519020-00006
    - KAAKKOLA S, "Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease", Int Rev Neurobiol, (20100000), vol. 95, pages 207 - 25
    - KISS LESOARES-DA-SILVA P, "Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility", J Med Chem, (20140000), vol. 57, no. 21, pages 8692 - 717
    - COTZIAS GC, "L-Dopa for Parkinsonism", N Engl J Med, (19680000), vol. 278, no. 11, page 630
    - FAHN SOAKES DSHOULSON IKIEBURTZ KRUDOLPH ALANG A et al., "Levodopa and the progression of Parkinson's disease", N Engl J Med, (20040000), vol. 351, no. 24, pages 2498 - 508
    - VERSCHUUR CVMSUWIJN SRBOEL JAPOST BBLOEM BRVAN HILTEN JJ et al., "Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease", New England Journal of Medicine, (20190000), vol. 380, no. 4, pages 315 - 24
    - HAUSER RA, "Levodopa: past, present, and future", Eur Neurol, (20090000), vol. 62, no. 1, pages 1 - 8
    - CALNE DBREID JLVAKIL SDRAO SPETRIE APALLIS CA et al., "Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa", Br Med J, (19710000), vol. 3, no. 5777, pages 729 - 32
    - NUTT JGWOODWARD WRANDERSON JL, "The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism", Ann Neurol, (19850000), vol. 18, no. 5, pages 537 - 43
    - LIEBERMAN AGOODGOLD AJONAS SLEIBOWITZ M, "Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease", Neurology, (19750000), vol. 25, no. 10, pages 911 - 6
    - MARKHAM CDIAMOND SGTRECIOKAS LJ, "Carbidopa in Parkinson disease and in nausea and vomiting of levodopa", Arch Neurol, (19740000), vol. 31, no. 2, pages 128 - 33
    - GERSHANIK OS, "Improving 1-dopa therapy: The development of enzyme inhibitors", Movement Disorders, (20150000), vol. 30, no. 1, pages 1 03 - 13
    - DELEU DNORTHWAY MGHANSSENS Y, "Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease", Clin Pharmacokinet, (20020000), vol. 41, no. 4, pages 261 - 309
    - KARHUNEN TTILGMANN CULMANEN IJULKUNEN IPANULA P, "Distribution of catechol-O-methyltransferase enzyme in rat tissues", J Histochem Cytochem, (19940000), vol. 42, no. 8, pages 1079 - 90
    - NUTT JGWOODWARD WRGANCHER STMERRICK D, "3-0-methyldopa and the response to levodopa in Parkinson's disease", Annals of Neurology, (19870000), vol. 21, pages 584 - 8
    - KAAKKOLA S, "Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease", Drugs, (20000000), vol. 59, no. 6, doi:10.2165/00003495-200059060-00004, pages 1233 - 50, XP002902132

DOI:   http://dx.doi.org/10.2165/00003495-200059060-00004
    - BONIFACIO MJPALMA PNALMEIDA LSOARES-DA-SILVA P, "Catechol-O-methyltransferase and its inhibitors in Parkinson's disease", CNS Drug Rev, (20070000), vol. 13, no. 3, doi:10.1111/j.1527-3458.2007.00020.x, pages 352 - 79, XP008154694

DOI:   http://dx.doi.org/10.1111/j.1527-3458.2007.00020.x
    - KAAKKOLA SGORDIN AMANNISTO PT, "General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase", Gen Pharmacol, (19940000), vol. 25, no. 5, doi:10.1016/0306-3623(94)90082-5, pages 813 - 24, XP025536733

DOI:   http://dx.doi.org/10.1016/0306-3623(94)90082-5
    - OLANOW CWWATKINS PB, "Tolcapone: an efficacy and safety review", Clin Neuropharmacol, (20070000), vol. 30, no. 5, pages 287 - 94
    - KISS LEFERREIRA HSTORRAO LBONIFACIO MJPALMA PNSOARES-DA-SILVA P et al., "Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase", J Med Chem, (20100000), vol. 53, no. 8, pages 3396 - 411
    - PALMA PNBONIFACIO MJLOUREIRO AISOARES-DA-SILVA P, "Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations", J Comput Chem, (20120000), vol. 33, no. 9, pages 970 - 86
    - BONIFACIO MCTORRAO MLOUREIRO AIWRIGHT LCSOARES-DA-SILVA P., "Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitor", Parkinsonism Relat Disord, (20120000), page 18
    - BONIFACIO MJTORRAO LLOUREIRO AIPALMA PNWRIGHT LCSOARES-DA-SILVA P., "Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.", Br J Pharmacol., (20150000), vol. 172, no. 7, pages 1739 - 52
    - BONIFACIO MJSUTCLIFFE JSTORRAO LWRIGHT LCSOARES-DA-SILVA P, "Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor", Neuropharmacology, (20140000), vol. 77, doi:10.1016/j.neuropharm.2013.10.014, pages 334 - 41, XP055195798

DOI:   http://dx.doi.org/10.1016/j.neuropharm.2013.10.014
    - BONIFACIO MJSOUSA FSOARES-DA-SILVA P, "Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys", Eur J Pharmacol, (20210000), vol. 892, page 173742
    - TISSOT RBARTHOLINI GPLETSCHER A., "Drug-induced changes of extracerebral dopa metabolism in man", Arch Neurol, (19690000), vol. 20, no. 2, pages 187 - 90
    - ROCHA JFFALCAO ASANTOS APINTO RLOPES NNUNES T et al., "Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations", Eur J Clin Pharmacol, (20140000), vol. 70, no. 9, doi:10.1007/s00228-014-1701-2, pages 1059 - 71, XP002765720

DOI:   http://dx.doi.org/10.1007/s00228-014-1701-2
    - ALMEIDA LROCHA JFFALCAO APALMA PNLOUREIRO AIPINTO R et al., "Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor", Clin Pharmacokinet, (20130000), vol. 52, no. 2, pages 139 - 51
    - STOCCHI FVACCA LRUGGIERI SOLANOW CW, "Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study", Arch Neurol, (20050000), vol. 62, no. 6, pages 905 - 10
    - BRUSA LPIERANTOZZI MBASSI AFEDELE ELUNARDI GGIACOMINI P et al., "Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome", Neurol Sci, (20040000), vol. 25, no. 2, pages 53 - 6
    - MYLLYLA VVSOTANIEMI KAILLI ASUOMINEN KKERANEN T, "Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease", European Journal Clinical Pharmacology, (19930000), vol. 45, pages 419 - 23
    - FALCAO ASANTOS AFERREIRA JJLEE AJHERNANDEZ BROCHA JF et al., "Decision-making process for opicapone's bedtime regimen", Movement Disorders, (20170000), page 32, URL: https://www.mdsabstracts.org/abstract/decision-making-process-for-opicapones-bedtime-regimen
    - NICE, "Parkinson's disease with end-of-dose motor fluctuations: opicapone", Evidence summary [ES9, (20170321), URL: https://www.nice.org.uk/advice/es9/chapter/Estimated-impact-for-the-NHS
    - DE LA FUENTE-FERNANDEZ RLU JQSOSSI VJIVAN SSCHULZER MHOLDEN JE et al., "Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover", Ann Neurol, (20010000), vol. 49, no. 3, pages 298 - 303
    - STOCCHI FOLANOW CW, "Continuous dopaminergic stimulation in early and advanced Parkinson's disease", Neurology, (20040000), vol. 62, no. 1, pages S56 - 63, XP002576738
    - LEES AJFERREIRA JRASCOL OREICHMANN HSTOCCHI FTOLOSA E et al., "Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA", Expert Rev Neurother, (20170000), vol. 17, no. 7, pages 649 - 59
    - FABBRI MFERREIRA JJLEES ASTOCCHI FPOEWE WTOLOSA E et al., "Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine", Mov Disord., (20180000), vol. 33, no. 10, pages 1528 - 39
    - FERREIRA JJLEES AROCHA JFPOEWE WRASCOL OSOARES-DA-SILVA P et al., "Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial", The Lancet Neurology, (20160000), vol. 15, no. 2, doi:10.1016/S1474-4422(15)00336-1, pages 154 - 65, XP029384199

DOI:   http://dx.doi.org/10.1016/S1474-4422(15)00336-1
    - LEES AJFERREIRA JRASCOL OPOEWE WROCHA JFMCCRORY M et al., "Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial", JAMA neurology., (20170000), vol. 74, no. 2, doi:10.1001/jamaneurol.2016.4703, pages 197 - 206, XP055844070

DOI:   http://dx.doi.org/10.1001/jamaneurol.2016.4703
    - TAKEDA ATAKAHASHI RTSUBOI YNOMOTO MMAEDA TNISHIMURA A et al., "Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations", Mov Disord, (20210000), vol. 36, no. 2, pages 415 - 23
    - FERREIRA JJLEES AROCHA JFPOEWE WRASCOL OSOARES-DA-SILVA P, "Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions", Eur J Neurol, (20190000), vol. 26, no. 7, pages 953 - 60
    - DEANE KHSPIEKER SCLARKE CE, "Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease", Cochrane Database Syst Rev, (20040000), vol. 4, page CD004553
    - SCHADE SMOLLENHAUER BTRENKWALDER C, "Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide", Movement Disorders Clinical Practice, (20200000), vol. 7, no. 3, pages 343 - 5
    - FERREIRA JJLEES AJPOEWE WRASCOL OROCHA JFKELLER B et al., "Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease", Neurology, (20180000), vol. 90, no. 21, pages el849 - e57
    - VOKURKA PBARRON ASUMARIA SSTOCKFORD LJARMAN PBHATIA K et al., "Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone", Mov Disord Clin Pract, (20200000), vol. 7, no. 8, pages 955 - 60
    - LEES AJ, "Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease", CNS neuroscience & therapeutics, (20080000), vol. 14, no. 1, pages 83 - 93
    - MULLER T., "Catechol-o-methyltransferase inhibitors in Parkinson's disease", Drugs, (20150000), vol. 75, no. 2, pages 157 - 74
    - REICHMANN HLEES AROCHA JFMAGALHAES DSOARES-DA-SILVA P, "investigators O. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study", Transl Neurodegener, (20200000), vol. 9, no. 1, page 9
    - HAUSER RAAUINGER P, "Determination of minimal clinically important change in early and advanced Parkinson's disease", Mov Disord, (20110000), vol. 26, no. 5, pages 813 - 8
    - LEES AFERREIRA JJROCHA JFRASCOL OPOEWE WSOARES-DA-SILVA PRI, "Safety Profile of Opicapone in the Management of Parkinson's Disease", J Parkinsons Dis, (20190000), vol. 9, no. 4, pages 733 - 40
    - STOCCHI FANTONINI ABARONE PTINAZZI MZAPPIA MONOFRJ M et al., "Early DEtection of wEaring off in Parkinson disease: the DEEP study", Parkinsonism Relat Disord, (20140000), vol. 20, no. 2, doi:10.1016/j.parkreldis.2013.10.027, pages 204 - 11, XP028827144

DOI:   http://dx.doi.org/10.1016/j.parkreldis.2013.10.027
    - STACY MBOWRON AGUTTMAN MHAUSER RHUGHES KLARSEN JP et al., "Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment", Mov Disord, (20050000), vol. 20, no. 6, pages 726 - 33
    - STACY M, "The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease", J Neural Transm (Vienna, (20100000), vol. 117, no. 7, pages 837 - 46, XP019853207
    - COLOMBO DABBRUZZESE GANTONINI ABARONE PBELLIA GFRANCONI F et al., "The ''gender factor'' in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study", ScientificWorldJournal, (20150000), vol. 2015, page 787451
    - G. EBERSBACHJ. FERREIRAA. ANTONINIA.T SANTOSD. MAGALHAESJ.F ROCHAP. SOARES-DA-SILVA, "Opicapone's added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson's disease: a post- hoc analysis of BIPARK-1 and II [abstract", Mov Disord, vol. 35, (20200000), URL: https://www.mdsabstracts.org/abstract/opicapones-added-benefit-as-a-first-line-adiunctive-therapy-to-levodopa-and-when-used-promptly-in-the-motor-fluctuations-spectrum-of-parkinsons-disease-a-post-hoc-analysis-of-bipark/
    - HAUSER RAGORDON MFMIZUNO YPOEWE WBARONE PSCHAPIRA AH et al., "Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release", Parkinsons Dis, (20140000), vol. 2014, page 467131
    - NISSINEN HKUOPPAMAKI MLEINONEN MSCHAPIRA AH, "Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis", Eur J Neurol, (20090000), vol. 16, no. 12, pages 1305 - 11
    - HAUSER RADECKERS FLEHERT P, "Parkinson's disease home diary: further validation and implications for clinical trials", Mov Disord, (20040000), vol. 19, no. 12, doi:10.1002/mds.20248, pages 1409 - 13, XP002998736

DOI:   http://dx.doi.org/10.1002/mds.20248
    - GOETZ CGTILLEY BCSHAFTMAN SRSTEBBINS GTFAHN SMARTINEZ-MARTIN P et al., "Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results", Mov Disord, (20080000), vol. 23, no. 15, pages 2129 - 70
    - CHAUDHURI KRSCHRAG AWEINTRAUB DRIZOS ARODRIGUEZ-BLAZQUEZ CMAMIKONYAN E et al., "The movement disorder society nonmotor rating scale: Initial validation study", Mov Disord, (20200000), vol. 35, no. 1, pages 116 - 33
    - JENKINSON C, FITZPATRICK R, PETO V, GREENHALF R, HYMAN N, "Development and validation of a short-form parkinson's disease questionnaire", Psychol Health, (19970000), vol. 12, pages 805 - 14
    - "Clinical global impressions", GUY W, ECDEU Assessment Manual for Psychopharmacology, Department of Health, Education, and Welfare, (19760000), pages 218 - 22
    - JENNER PMCCREARY ACSCHELLER DK, "Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression", J Neural Transm (Vienna, (20110000), vol. 118, no. 12, doi:10.1007/s00702-011-0703-9, pages 1691 - 702, XP019980284

DOI:   http://dx.doi.org/10.1007/s00702-011-0703-9
    - OLANOW CWOBESO JASTOCCHI F, "Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications", Lancet Neurol, (20060000), vol. 5, no. 8, doi:10.1016/S1474-4422(06)70521-X, pages 677 - 87, XP024969172

DOI:   http://dx.doi.org/10.1016/S1474-4422(06)70521-X
    - OLANOW CWOBESO JASTOCCHI F, "Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease", Nat Clin Pract Neurol, (20060000), vol. 2, no. 7, pages 382 - 92
    - PICCONI BPICCOLI GCALABRESI P, "Synaptic dysfunction in Parkinson's disease", Adv Exp Med Biol, (20120000), vol. 970, pages 553 - 72
    - STOCCHI FRASCOL OKIEBURTZ KPOEWE WJANKOVIC JTOLOSA E et al., "Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study", Ann Neurol, (20100000), vol. 68, no. 1, pages 18 - 27
    - SMITH LAJACKSON MJAL-BARGHOUTHY GROSE SKUOPPAMAKI MOLANOW W et al., "Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates", Mov Disord, (20050000), vol. 20, no. 3, pages 306 - 14
    - MUHLACK SHERRMANN LSALMEN SMULLER T, "Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition", J Neural Transm (Vienna, (20140000), vol. 121, no. 11, pages 1357 - 66
    - KUOPPAMAKI MKORPELA KMARTTILA RKAASINEN VHARTIKAINEN PLYYTINEN J et al., "Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily", Eur J Clin Pharmacol, (20090000), vol. 65, no. 5, pages 443 - 55, XP019703953
    - LOEWEN GLEWITT POLANOW CWKIEBURTZ KLIANG GJIMENEZ R et al., "Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson's Disease [abstract", Mov Disord, vol. 34, (20210315), URL: https://www.mdsabstracts.orabstract/pharmacokinetics-of-opicapone-and-effect-on-comt-and-levodopa-pharmacokinetics-in-patients-with-parkinsons-disease/
    - WATERS CHKURTH MBAILEY PSHULMAN LMLEWITT PDORFLINGER E et al., "Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment", The Tolcapone Stable Study Group. Neurology, (19970000), vol. 49, no. 3, pages 665 - 71
    - HAUSER RAPANISSET MABBRUZZESE GMANCIONE LDRONAMRAJU NKAKARIEKA A, "Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease", Mov Disord, (20090000), vol. 24, no. 4, pages 541 - 50
    - BROOKS DJSAGAR H, "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study", J Neurol Neurosurg Psychiatry, (20030000), vol. 74, no. 8, pages 1071 - 9
    - POEWE WHDEUSCHL GGORDIN AKULTALAHTI ERLEINONEN M, "Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6- month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study", Acta Neurol Scand, (20020000), vol. 105, no. 4, pages 245 - 55
    - Early ParkinSon with L-DOPA and OpicapoNe [EPSILON] study, (20210500), URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005011-52/CZ
    - OpicApone Sleep dISorder (OASIS) study, (20210500), URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001176-15/DE
    - STORCH ASCHNEIDER CBWOLZ MSTURWALD YNEBE AODIN P et al., "Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications", Neurology, (20130000), vol. 80, no. 9, pages 800 - 9
    - ANTONINI ATINAZZI MABBRUZZESE GBERARDELLI ACHAUDHURI KRDEFAZIO G et al., "Pain in Parkinson's disease: facts and uncertainties", Eur J Neurol, (20180000), vol. 25, no. 7, pages 917 - e69
    - NEBE AEBERSBACH G, "Pain intensity on and off levodopa in patients with Parkinson's disease", Mov Disord, (20090000), vol. 24, no. 8, pages 1233 - 7
    - OpiCapone Effect on motor fluctuations and pAiN [OCEAN] study, (20210500), URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001175-32/PT
    - POEWE WANTONINI A, "Novel formulations and modes of delivery of levodopa", Mov Disord, (20150000), vol. 30, no. 1, pages 114 - 20
    - GILADI NCARACO YGUREVICH TDJALDETTI RADAR LRACHMILEWITZ MINEI T et al., "ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD [abstract", Mov Disord, vol. 32, (20170000), URL: http://www.mdsabstracts.org/abstract/nd0612-levodopacarbidopa-for-subcutaneous-infusion-achieves-stable-levodopa-plasma-levels-when-administered-in-low-and-high-doses-in-patients-with-pd/
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.